Fluoropyrimidine-associated grade 3/4 toxicity was increased in FOLFOX-4-treated patients experiencing a malfunction compared with those who did not ( 97 out of 155 vs 452 out of 825 patients ) , predominantly with increased grade 3/4 neutropenia ( 53.5 % vs 39.8 % ) .